We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Kicks Off Assessment of Novartis Drug for Rare Blood Disorder PNH
ICER Kicks Off Assessment of Novartis Drug for Rare Blood Disorder PNH
The Institute for Clinical and Economic Review (ICER) will assess the comparative clinical effectiveness and economic value of Novartis’s drug iptacopan for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare genetic blood disease.
